Potency testing is becoming an important area of innovation within the market. Cell and gene therapy developers require assays capable of demonstrating relevant biological activity and supporting product consistency. The development of mechanism-of-action-related potency assays remains an important analytical challenge across advanced therapy programs.

The Cell and Gene Therapy QC & Analytics Market is becoming increasingly important as pharmaceutical and biotechnology companies expand the development and commercialization of advanced therapies. The global market is estimated at approximately US$ 1.88 billion in 2025 and is projected to reach around US$ 5.38 billion by 2034, representing a CAGR of 12.40% during 2026–2034. The rapid development of cell therapies, gene therapies, and genetically modified cellular products is increasing demand for sophisticated quality control and analytical solutions throughout research, development, manufacturing, and release testing.

Cell and gene therapies involve complex biological materials that require extensive characterization to demonstrate identity, purity, potency, safety, and consistency. Consequently, cell and gene therapy analytics are becoming an essential part of advanced therapy manufacturing. Increasing regulatory expectations, expanding clinical pipelines, and the transition from research-scale production to commercial manufacturing are creating significant opportunities for analytical technology providers and contract testing organizations.

What Is Driving the Cell and Gene Therapy QC & Analytics Market?

The increasing complexity of advanced therapies is one of the primary factors supporting market expansion. Unlike many conventional pharmaceutical products, cell and gene therapies can involve living cells, viral vectors, nucleic acids, and other highly sensitive biological components.

Key cell and gene therapy market trends include:

• Expansion of clinical pipelines: More cell and gene therapy candidates are progressing through clinical development.
• Increasing manufacturing complexity: Commercial-scale production requires highly controlled analytical workflows.
• Growing regulatory scrutiny: Developers must generate robust analytical evidence to demonstrate product quality and patient safety.
• Demand for rapid testing: Faster analytical methods can support shorter manufacturing and release timelines.
• Growth of contract testing: Smaller biotechnology companies increasingly use specialized external laboratories for analytical development and quality testing.
• Technological advancement: Automation, molecular testing, flow cytometry, sequencing, and advanced bioassays are improving analytical capabilities.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00042196

Why Is Quality Control Critical for Cell and Gene Therapies?

Cell and gene therapy quality control is fundamental because minor changes in manufacturing conditions can potentially affect the characteristics and performance of a biological product. Developers therefore require comprehensive analytical strategies throughout the product lifecycle.

Important quality attributes can include:

• Product identity
• Purity and impurities
• Potency
• Viability
• Cell phenotype
• Genetic characteristics
• Microbial contamination
• Adventitious agents
• Residual process components
• Vector characteristics

Analytical testing provides the evidence required to evaluate these attributes and establish product consistency. As manufacturing processes become more standardized, analytical methods must also evolve to support increasingly complex products.

How Are Advanced Analytical Technologies Transforming the Market?

Technological innovation is expanding the capabilities of cell and gene therapy testing. Traditional laboratory methods are increasingly being supplemented by advanced molecular, cellular, and bioanalytical technologies.

Flow cytometry can enable detailed characterization of cellular populations and surface markers, while polymerase chain reaction and sequencing technologies can support genetic characterization. Mass spectrometry and other analytical techniques can provide additional information about product composition and impurities.

Automation is also becoming increasingly relevant. Automated sample preparation, data acquisition, and analysis can improve laboratory throughput while reducing manual variability.

The integration of sophisticated software and data-management systems is another emerging opportunity. Advanced therapy manufacturers increasingly need analytical workflows that can generate traceable data suitable for regulated environments.

What Role Does Potency Testing Play?

Potency assays are an important component of advanced therapy quality control because they are designed to evaluate whether a product demonstrates the intended biological activity. Developing reliable potency assays can be challenging because the mechanisms of action may be complex and product-specific.

For cell therapies, potency can involve evaluating cellular function or biological activity. For gene therapies, assays may assess functional expression or other product-specific biological effects.

This complexity creates opportunities for companies specializing in assay development and validation. As more advanced therapies move toward commercialization, standardized and fit-for-purpose potency testing is expected to remain a significant area of investment.

How Are Regulatory Requirements Influencing Market Growth?

Regulatory expectations are a major market driver. Developers must establish analytical methods capable of demonstrating that advanced therapy products consistently meet predefined quality specifications.

The need for method validation, process characterization, comparability assessment, and batch-release testing is encouraging companies to strengthen their analytical infrastructure.

For biotechnology companies with limited internal capabilities, specialized contract research and contract testing organizations can provide access to validated laboratory platforms and technical expertise. This is supporting the expansion of the cell and gene therapy contract testing market alongside broader QC and analytics demand.

Who Are the Key Companies in the Cell and Gene Therapy QC & Analytics Market?

The competitive landscape includes global life sciences companies, analytical service providers, laboratory technology companies, and contract research organizations. Prominent companies include:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Sartorius AG
• Danaher Corporation
• Eurofins Scientific
• Charles River Laboratories International, Inc.
• Labcorp Drug Development
• Catalent, Inc.
• Bio-Rad Laboratories, Inc.
• WuXi AppTec

Companies are focusing on analytical platform development, laboratory expansion, assay capabilities, manufacturing support, and strategic partnerships. Contract testing and analytical development services are particularly relevant as emerging therapy developers seek specialized capabilities without building every testing function internally.

Purchase a Copy of this report: https://www.theinsightpartners.com/buy/TIPRE00042196

What Is the Future Outlook for the Cell and Gene Therapy QC & Analytics Market?

The Cell and Gene Therapy QC & Analytics Market is projected to grow from approximately US$ 1.88 billion in 2025 to US$ 5.38 billion by 2034, expanding at a 12.40% CAGR during 2026–2034. This growth reflects the increasing analytical requirements associated with advanced therapies as they progress from early-stage research toward larger-scale manufacturing and commercialization.

Future opportunities are expected to emerge around:

• Advanced potency assays
• Rapid microbial testing
• Flow cytometry and cellular characterization
• Next-generation sequencing
• Viral vector characterization
• Automated analytical workflows
• Process analytical technologies
• Data-integrated QC platforms
• Contract analytical and testing services

As cell and gene therapy manufacturing becomes more sophisticated, analytical testing will remain closely connected to product quality, process consistency, regulatory compliance, and commercialization. The combination of expanding therapy pipelines, increasingly complex manufacturing processes, and growing demand for reliable analytical evidence is expected to support continued investment across the Cell and Gene Therapy QC & Analytics Market.

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish

Related Reports:

Gene Therapy CDMO Market Growth, Share, and Forecast (2026-2034)

Cell Therapy CDMO Market Size, Share and Forecast by 2031

About Us

The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.

Contact US

Contact Person: Ankit Mathur

Phone: +1-646-491-9876

E-mail : [email protected]